Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/12/16 18:49:03」(JST)

wiki en

Ulobetasol (or halobetasol) is a corticosteroid used to treat psoriasis. It is a group I corticosteroid under the US classification, the most potent class of such drugs. Halobetasol propionate is usually supplied as a 0.05% topical cream.

External links

halobetasol at the US National Library of Medicine Medical Subject Headings (MeSH)

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 外陰部硬化性苔癬 vulvar lichen sclerosus
2. 乾癬の治療 treatment of psoriasis
3. 皮膚サルコイドーシスの管理 management of cutaneous sarcoidosis
4. 外陰部の扁平苔癬 vulvar lichen planus
5. 思春期前の小児における外陰膣に関する愁訴 vulvovaginal complaints in the prepubertal child

English Journal

Impurity profiling and a stability-indicating UPLC method development and validation for the estimation of related impurities of halobetasol propionate in halobetasol propionate 0.05% (w/w) cream.

Prakash L1, Malipeddi H2, Subbaiah BV3, Lakka NS3.
Journal of chromatographic science.J Chromatogr Sci.2015 Jan;53(1):112-21. doi: 10.1093/chromsci/bmu027. Epub 2014 May 2.
A simple, short and stability-indicating reverse phase-ultra-performance liquid chromatography method was developed and validated for the quantitative determination of related impurities of halobetasol propionate in halobetasol propionate 0.05% cream formulation. The proposed method was developed on
PMID 24795078

Quantification of halobetasol propionate and its impurities present in topical dosage forms by stability-indicating LC method.

Nalwade S1, Reddy VR2, Kulkarni D3, Todamal S3.
Journal of chromatographic science.J Chromatogr Sci.2015 Jan;53(1):127-34. doi: 10.1093/chromsci/bmu029. Epub 2014 Apr 30.
A novel, sensitive, stability-indicating, gradient, reverse-phase high-performance liquid chromatographic method has been developed for quantitative determination of halobetasol propionate and its impurities in topical dosage forms. The chromatographic separation was achieved on a Phenomenex Synergi
PMID 24784115

An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis.

Czarnowicki T1, Linkner RV2, Suárez-Fariñas M3, Ingber A4, Lebwohl M2.
Journal of the American Academy of Dermatology.J Am Acad Dermatol.2014 Nov;71(5):954-959.e1. doi: 10.1016/j.jaad.2014.05.040. Epub 2014 Jun 11.
BACKGROUND: Topical corticosteroids are the most common first-line treatment for psoriasis. Tachyphylaxis, a decreased response to treatment with repetitive application of the drug, is a controversial phenomenon associated with topical corticosteroid treatment.OBJECTIVE: We sought to prove or dispro
PMID 24929883

「ULTRAVATE」

Ulobetasol
Systematic (IUPAC) name
	(6α,11β,16β)-21-chloro-6,9-difluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601060
Legal status	?
Identifiers
CAS number	98651-66-2
ATC code	D07AC21
PubChem	CID 5311167
ChemSpider	4470691
UNII	9P6159HM7T
KEGG	D08660
ChEMBL	CHEMBL1201360
Synonyms	(6S,8S,9S,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Chemical data
Formula	C22H27ClF2O4
Mol. mass	428.897
	SMILES ClCC(=O)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@@H]3C)C)C;
	InChI InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1 ; Key:LEHFPXVYPMWYQD-XHIJKXOTSA-N ;
(what is this?) (verify)